July 12, 2014 8:52 PM ET


Company Overview of DrugAbuse Sciences, Inc.

Company Overview

DrugAbuse Sciences, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of alcohol and drug addictions. It offers Naltrexone Depot, a sustained-release formulation of Naltrexone for the treatment of alcohol and opiate addictions; DAS-431 for the treatment of cocaine addiction; and Buprenorphine Depot, a sustained-release formulation of buprenorphine for the treatment of heroin and various opiate addictions. The company was founded in 1994 and is based in Menlo Park, California with an additional office in Paris, France.

1430 Obrien Drive

Suite E

Menlo Park, CA 94025

United States

Founded in 1994

19 Employees



Key Executives for DrugAbuse Sciences, Inc.

Chief Executive Officer
Chairman and President
Age: 69
Chief Financial Officer and Vice President of Business Development
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Aurogen Incorporated United States
Dynova Laboratories, LLC United States
Stat-Trade, Inc. United States
Vaccinex, Inc. United States
NeuroTherapeutics Pharma, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DrugAbuse Sciences, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.